---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090094"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-08-04T12:25:32+00:00"
generated_at: "2026-08-04T12:30:09.093470+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma reports Q2 2026 results; in-licenses two late-stage assets, ciprocopan approved in China, raises $115M

## Summary
- In-licensed ex-China rights to ciprocopan (NXP100) and NXP200 from Haisco; ciprocopan approved in China for PNH in July 2026.
- Completed follow-on offering in July 2026 raising $115M gross proceeds, extending cash runway into 1H 2029.
- Cash and equivalents $22.2M as of June 30, 2026, down from $31.6M at Dec 31, 2025.
- Net loss for Q2 2026 was $7.0M vs $6.3M in Q2 2025; R&D expenses rose to $4.7M from $3.6M.
- U.S. IND submission for ciprocopan expected in 4Q2026; NXP200 IND also expected in 4Q2026.

## SEC filing metadata
- accession: 0001104659-26-090094
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-08-04T12:25:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/0001104659-26-090094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926090094/tm2622125d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090094
- JSON: https://secwatch.observer/filing/0001104659-26-090094.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.